Telix starts Pixclara rollout: what it means for Telix stock

Published on 10/13/2026 at 01:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Telix posted USD 477.00 million revenue in H1 2026, up 22.00 percent year over year. For Telix stock, Pixclara adds a second FDA-approved product.

Telix began U.S. commercial availability for Pixclara after first patients received the glioma imaging drug on October 6, 2026.
Telix reported USD 477.00 million in first-half 2026 revenue, up 22.00 percent year over year.
The company guided to USD 950.00 million-USD 970.00 million of 2026 revenue.
Telix's proposed ITM transaction carries USD 1.65 billion of upfront consideration and targets more than USD 1.30 billion of pro forma 2026 revenue and income.

Telix, AU000000TLX2, Illustration mit AI erstellt.

Telix Pharmaceuticals (ISIN AU000000TLX2) had reported first U.S. patients dosed with Pixclara on October 6, 2026, starting commercial availability for the glioma imaging drug, according to Yahoo Finance. The doses were administered at centers in Indianapolis and Cleveland, giving Telix a commercial product beyond its prostate imaging portfolio.

Pixclara moves into commercial use

The October 6 announcement marked the first U.S. commercial dosing of Pixclara, an FDA-approved positron emission tomography drug for glioma imaging. Mugglehead reported that the company had forecast USD 950.00 million-USD 970.00 million of 2026 revenue, while the launch release did not assign a separate sales target to Pixclara.

The launch also broadens the operating base behind that outlook. Telix's first-half 2026 revenue reached USD 477.00 million, a 22.00 percent year-over-year increase, according to Mugglehead.

What does Pixclara mean for revenue?

The answer depends on utilization, reimbursement and distribution rather than regulatory status alone. Pixclara's first commercial doses create an additional product channel, while the existing 2026 revenue outlook remains USD 950.00 million-USD 970.00 million.

Three milestones reshape the story

On September 14, 2026, Telix received FDA approval for Pixclara, with the drug evaluated in a safety population of 382 patients, according to MarketScreener. On September 21, 2026, Telix announced its planned ITM transaction with USD 1.65 billion of upfront consideration, according to Finanznachrichten. The combined organization is expected to generate more than USD 1.30 billion of pro forma 2026 revenue and income.

Stock context and next milestone

The ITM transaction adds isotope production and a therapeutic pipeline to Telix's diagnostic platform, but it also introduces approval and execution conditions. The agreement is subject to shareholder and regulatory approvals, with closing expected by the end of fiscal year 2026.

Telix's next commercial test is the pace at which U.S. centers use Pixclara alongside other diagnostic findings. The October 6 launch, USD 477.00 million of first-half revenue and USD 950.00 million-USD 970.00 million full-year guidance give investors three concrete markers for judging that rollout.

Telix stock stays tied to execution

Telix's dated milestones point to a company moving from regulatory approval toward commercialization and integration. The further course of trading is shown by the continuously updated real-time quote of Telix stock.